The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis

Abstract FOLFIRINOX has been one of the first-line options for advanced pancreatic cancer, even though it induces significant adverse effects. Several institutions have begun using modified FOLFIRINOX to decrease its side effects and increase its tolerability. We systematically investigated the outc...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Hongxuan Tong, Zhu Fan, Biyuan Liu, Tao Lu
Format: article
Langue:EN
Publié: Nature Portfolio 2018
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/13b0bd8f9db545da901879f0ffc5158e
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!